Published in Nature on September 29, 2010
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Periodontal Disease and Breast Cancer: Prospective Cohort Study of Postmenopausal Women. Cancer Epidemiol Biomarkers Prev (2015) 2.68
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev (2014) 1.86
Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell (2014) 1.70
Mammary gland development. Wiley Interdiscip Rev Dev Biol (2013) 1.64
Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood (2014) 1.60
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med (2016) 1.55
NF-κB, stem cells and breast cancer: the links get stronger. Breast Cancer Res (2011) 1.51
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
Denosumab treatment for fibrous dysplasia. J Bone Miner Res (2012) 1.26
A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1. Cancer Cell (2013) 1.21
The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol (2011) 1.19
Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res (2011) 1.16
Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev (2012) 1.15
Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res (2012) 1.14
Reproductive history and breast cancer risk. Breast Cancer (2012) 1.14
Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity. Autophagy (2014) 1.14
Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc Natl Acad Sci U S A (2011) 1.13
Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development (2013) 1.11
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08
Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest (2011) 1.05
Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol (2012) 1.02
Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells. Mol Endocrinol (2013) 1.00
Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm Cancer (2010) 0.99
LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat Med (2016) 0.99
Biology of breast cancer in young women. Breast Cancer Res (2014) 0.98
Denosumab: a new option in the treatment of bone metastases from urological cancers. Onco Targets Ther (2012) 0.98
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag (2012) 0.97
Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis. Endocrinology (2015) 0.96
Targeting RANKL in metastasis. Bonekey Rep (2014) 0.95
From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol (2011) 0.94
Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev (2013) 0.94
Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol (2011) 0.93
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine (2015) 0.93
Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab (2011) 0.92
Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol (2014) 0.92
Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. Cancer Res (2011) 0.92
Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J Biol Chem (2012) 0.92
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop (2013) 0.90
Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium. Breast Cancer Res (2013) 0.90
Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer (2012) 0.88
Bone structural components regulating sites of tumor metastasis. Curr Osteoporos Rep (2011) 0.88
Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene (2014) 0.87
RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res (2016) 0.87
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res (2013) 0.87
Research resource: progesterone receptor targetome underlying mammary gland branching morphogenesis. Mol Endocrinol (2013) 0.87
ER and PR signaling nodes during mammary gland development. Breast Cancer Res (2012) 0.86
Genetic polymorphism of the OPG gene associated with breast cancer. BMC Cancer (2013) 0.86
Nuclear receptors in bone physiology and diseases. Physiol Rev (2013) 0.86
Contribution of bone tissue modulus to breast cancer metastasis to bone. Cancer Microenviron (2011) 0.85
Targeted treatments of bone metastases in patients with lung cancer. Front Oncol (2014) 0.85
Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance. Stem Cells Transl Med (2014) 0.83
Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res (2012) 0.83
Loss of SFRP1 promotes ductal branching in the murine mammary gland. BMC Dev Biol (2012) 0.83
Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study. Eur J Epidemiol (2014) 0.82
Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury. PLoS One (2012) 0.82
Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. J Carcinog (2011) 0.82
Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling. Mol Cell Biol (2011) 0.82
Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev Res (Phila) (2011) 0.82
The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes. Endocr Relat Cancer (2015) 0.81
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res (2015) 0.81
Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line. PLoS One (2012) 0.80
The innovative medicines initiative: a public private partnership model to foster drug discovery. Comput Struct Biotechnol J (2013) 0.80
Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer. Oncotarget (2016) 0.80
Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis. Cancer Sci (2015) 0.80
Steroid Hormones, Steroid Receptors, and Breast Cancer Stem Cells. J Mammary Gland Biol Neoplasia (2015) 0.80
Role of RANKL/RANK in primary and secondary breast cancer. World J Orthop (2013) 0.79
Denosumab: A comprehensive review. South Asian J Cancer (2013) 0.79
Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ. BMC Cancer (2015) 0.79
The role of the bone microenvironment in skeletal metastasis. J Bone Oncol (2012) 0.79
Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion. Oncoimmunology (2015) 0.78
Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice. Carcinogenesis (2014) 0.78
Modeling cutaneous squamous carcinoma development in the mouse. Cold Spring Harb Perspect Med (2014) 0.78
Disrupting Na(+),HCO3(-)-cotransporter NBCn1 (Slc4a7) delays murine breast cancer development. Oncogene (2015) 0.78
Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Res (2016) 0.77
Cripto-1 Ablation Disrupts Alveolar Development in the Mouse Mammary Gland through a Progesterone Receptor-Mediated Pathway. Am J Pathol (2015) 0.77
Co-expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell carcinoma. Odontology (2013) 0.77
Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients. Biomed Res Int (2014) 0.77
Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Oncotarget (2016) 0.76
High hopes for RANKL: will the mouse model live up to its promise? Breast Cancer Res (2011) 0.76
Cancer: RANKL inhibition—a new weapon against breast cancer? Nat Rev Endocrinol (2011) 0.76
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol (2012) 0.76
RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer. Oncotarget (2017) 0.76
Epithelial cell identity in hyperplastic precursors of breast cancer. Chin J Cancer (2015) 0.75
Prospects of adjuvant RANKL inhibition in breast cancer? Cell Death Dis (2015) 0.75
The effects of diet induced obesity on breast cancer associated pathways in mice deficient in SFRP1. Mol Cancer (2014) 0.75
Bone-targeted therapy in metastatic breast cancer - all well-established knowledge? Breast Care (Basel) (2014) 0.75
Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS One (2015) 0.75
RANK/RANKL pathway in cancer: Biological activity beyond bone? J Bone Oncol (2012) 0.75
RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers. EBioMedicine (2015) 0.75
Potential suppressive effects of gentian violet on human breast cancer MDA-MB-231 cells in vitro: Comparison with gemcitabine. Oncol Lett (2016) 0.75
Caldecrin: A pancreas-derived hypocalcemic factor, regulates osteoclast formation and function. World J Biol Chem (2015) 0.75
Chronic stress, sympathetic activation and skeletal metastasis of breast cancer cells. Bonekey Rep (2015) 0.75
RANK rs1805034 T>C polymorphism is associated with susceptibility of esophageal cancer in a Chinese population. PLoS One (2014) 0.75
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A (1992) 8.59
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene (2000) 4.90
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst (2003) 3.83
A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A (1998) 3.23
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell (2001) 3.10
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell (2006) 2.91
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A (2010) 2.45
Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst (2008) 2.45
The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol (2009) 1.67
Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab (1999) 1.63
Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis (1996) 1.19
Progesterone involvement in breast development and tumorigenesis--as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids (2003) 1.19
Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Res (2002) 1.18
Progestins and breast cancer. Breast Dis (2006) 1.16
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol (2006) 1.14
Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids (2000) 1.03
U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med (2005) 7.58
Use of e-Health services between 1999 and 2002: a growing digital divide. J Am Med Inform Assoc (2004) 3.56
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med (2011) 3.16
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Family medicine in 2018. Can Fam Physician (2010) 2.24
Stability and aggregation of metal oxide nanoparticles in natural aqueous matrices. Environ Sci Technol (2010) 2.21
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res (2012) 1.98
Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr (2004) 1.93
Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys (2010) 1.82
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.68
American Society for Radiation Oncology (ASTRO) 2012 Workforce Study: the radiation oncologists' and residents' perspectives. Int J Radiat Oncol Biol Phys (2013) 1.58
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem (2002) 1.54
Overview and recommendations for medical screening and diagnostic evaluation for postdeployment lung disease in returning US warfighters. J Occup Environ Med (2012) 1.54
Sexual health experiences of adolescents in three Ghanaian towns. Int Fam Plan Perspect (2003) 1.53
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther (2010) 1.53
CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia (2006) 1.52
Functional analysis of elective nephron-sparing surgery vs radical nephrectomy for renal tumors larger than 4 cm. Urology (2012) 1.46
Electron microscopic and proteomic comparison of terminal branches of the trigeminal nerve in patients with and without migraine headaches. Plast Reconstr Surg (2014) 1.46
Practical guidance: the use of social media in oncology practice. J Oncol Pract (2012) 1.44
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate (2008) 1.42
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35
How the optic nerve allocates space, energy capacity, and information. J Neurosci (2009) 1.34
Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem (2004) 1.30
4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol (2002) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Cleavage of neuregulin-1 by BACE1 or ADAM10 protein produces differential effects on myelination. J Biol Chem (2011) 1.25
Severe spotted fever group rickettsiosis, Australia. Emerg Infect Dis (2007) 1.23
Diagnosis and surgical management of colovesical fistulas due to sigmoid diverticulitis. J Urol (2009) 1.23
Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res (2006) 1.18
Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone (2008) 1.18
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res (2002) 1.17
British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med (2011) 1.17
Robotic technology and the translation of open radical prostatectomy to laparoscopy: the early Frankfurt experience with robotic radical prostatectomy and one year follow-up. Eur Urol (2003) 1.15
Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis (2004) 1.14
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther (2008) 1.13
Cortisol in hair, body mass index and stress-related measures. Biol Psychol (2012) 1.12
Intraindividual stability of hair cortisol concentrations. Psychoneuroendocrinology (2011) 1.12
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res (2010) 1.11
A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene (2004) 1.11
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res (2003) 1.10
A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine (2009) 1.09
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev (2007) 1.08
Management of adenoid cystic carcinoma of the breast: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys (2011) 1.07
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry (2005) 1.06
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry (2005) 1.05
A systems biology dynamical model of mammalian G1 cell cycle progression. Mol Syst Biol (2007) 1.05
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res (2005) 1.04
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther (2012) 1.03
The number, size, and type of axons in rat subcortical white matter on left and right sides: a stereological, ultrastructural study. J Neurocytol (2003) 1.03
Mutation of the murine Bloom's syndrome gene produces global genome destabilization. Mol Cell Biol (2006) 1.01
Pathway analysis of high-throughput biological data within a Bayesian network framework. Bioinformatics (2011) 1.00
Incidence, clinical symptoms and management of rectourethral fistulas after radical prostatectomy. J Urol (2009) 0.99
Cortisol in hair and the metabolic syndrome. J Clin Endocrinol Metab (2013) 0.99
The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys (2009) 0.98
Mayo Clinic experience with very rare exocrine pancreatic neoplasms. Pancreas (2010) 0.98
Distribution of axon diameters in cortical white matter: an electron-microscopic study on three human brains and a macaque. Biol Cybern (2014) 0.97
An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve (2009) 0.96
Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol (2013) 0.95
Single center comparison of anastomotic strictures after radical perineal and radical retropubic prostatectomy. Urology (2009) 0.95
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer (2009) 0.94
Practice parameter: utility of electrodiagnostic techniques in evaluating patients with suspected peroneal neuropathy: an evidence-based review. Muscle Nerve (2005) 0.94
ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood (2006) 0.94
Renal transplantation in the elderly: surgical complications and outcome with special emphasis on the Eurotransplant Senior Programme. Nephrol Dial Transplant (2008) 0.94
RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat (2014) 0.93
Craniospinal irradiation with spinal IMRT to improve target homogeneity. Int J Radiat Oncol Biol Phys (2007) 0.93
Early experiences with e-health services (1999-2002): promise, reality, and implications. Med Care (2006) 0.93
Crystal-packing-induced antiferromagnetic interactions of metallocenes: cyanonickelocenes, -cobaltocenes, and -ferrocenes. Chemistry (2008) 0.93
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
Human cytomegalovirus infection alters PC3 prostate carcinoma cell adhesion to endothelial cells and extracellular matrix. Neoplasia (2006) 0.91
Osteosarcomas of the mandible: are they different from other tumor sites? Crit Rev Oncol Hematol (2011) 0.91
RANKL inhibition: from mice to men (and women). Adv Exp Med Biol (2007) 0.90
Levels of Speech Usage: A Self-Report Scale for Describing How People Use Speech. J Med Speech Lang Pathol (2008) 0.88
CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer. Mol Med Rep (2011) 0.87
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol (2007) 0.87
Riluzole for ALS: what is the evidence? Amyotroph Lateral Scler Other Motor Neuron Disord (2003) 0.87
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res (2013) 0.87
Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.85
Newborn, carrier, and early childhood screening recommendations for fragile X. Pediatrics (2012) 0.85
Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells (2013) 0.85
Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone (2010) 0.84
Recurrent invasive lobular carcinoma presenting as a ruptured breast implant. Radiol Oncol (2011) 0.84
Dual inactivation of Hus1 and p53 in the mouse mammary gland results in accumulation of damaged cells and impaired tissue regeneration. Proc Natl Acad Sci U S A (2009) 0.84
Correlates of quality of life in ALS: Lessons from the minocycline study. Amyotroph Lateral Scler (2010) 0.84
The cortisol awakening response in infants: ontogeny and associations with development-related variables. Psychoneuroendocrinology (2012) 0.84
Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. PLoS One (2007) 0.83